Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Current Cancer Therapy Reviews
Title: Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Volume: 7 Issue: 1
Author(s): Eudocia C. Quant, Catherine L. Nutt, Daphne Wang and Tracy T. Batchelor
Affiliation:
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Abstract: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Export Options
About this article
Cite this article as:
C. Quant Eudocia, L. Nutt Catherine, Wang Daphne and T. Batchelor Tracy, Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma, Current Cancer Therapy Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339411794474146
DOI https://dx.doi.org/10.2174/157339411794474146 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Oxidative Stress Modulation and Radiosensitizing Effect of Quinoxaline-1,4-Dioxides Derivatives
Anti-Cancer Agents in Medicinal Chemistry Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Early Post-Operative Neuroimaging After Surgery for Malignant Glioma
Current Medical Imaging Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells
Medicinal Chemistry A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
Current Medicinal Chemistry miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets